Drug History and SLE Laboratory Findings Among Iraqi Patients: A Hospital-Based Study

伊拉克系统性红斑狼疮患者的用药史和实验室检查结果:一项基于医院的研究

阅读:2

Abstract

BACKGROUND AND AIMS: Systemic lupus erythematosus (SLE) is a recurrent and remitting autoimmune disease that affects many organ systems. It is more common in women of reproductive age, with a 9:1 female preponderance. Due to the lack of data from developing countries, our study aims to provide comprehensive insights into the drug history and SLE laboratory findings among Iraqi patients. METHODOLOGY: It is a cross-sectional study at the Baghdad Medical Complex in Iraq. All SLE patients who attended the outpatient clinic between September and December 2022 were included. The patients included those who came for follow-up, deterioration of their symptoms, or a first-time diagnosis. RESULTS: SLE is much more prevalent among female patients. The ratio of female and male patients in our study was 19:1. This disease is more prevalent in the reproductive age group, with the mean age of our patients being 34 years, although the range spans from 15 to 85 years. The most prevalent signs and symptoms among the patients were photosensitivity (79.5%), hair loss (74%), and malar rash (72.5%). Most patients had positive antinuclear antibodies and anti-double-stranded DNA antibodies, with 73.5% and 65% testing positive, respectively. CONCLUSION: In conclusion, this study represents an important step in exploring SLE within Iraq, providing invaluable insights into its management and laboratory findings. The findings contribute to the global understanding of SLE. This study underscores the significance of Iraq's genetic backgrounds and environmental conditions, which are different from those of other countries, in the process of enhancing the global medical literature and expanding our understanding of SLE patterns around the world.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。